Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses the possibility of administering immunotherapy as treatment for patients with HER2-positive breast cancer.
Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, at UNC-Chapel Hill, UNC Linebarger Comprehensive Cancer Center, discusses why brain metastases is such a prominent issue in patients with breast cancer in an interview during the 2016 OncLive State of the Science Summit on Metastatic Breast Cancer.
Kandace McGuire, MD, associate professor of Surgery, UNC Department of Surgery, Division of Surgical Oncology, UNC School of Medicine, discusses the evolving role of surgery in the treatment of patients with metastatic breast cancer.
Norman E. Sharpless, MD, discusses the impact of the CheckMate-069 trial, the toxicities that are associated with nivolumab (Opdivo)/ipilimumab (Yervoy), and what the future holds for immunotherapy combinations in the field of melanoma.
Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, discusses assessing treatment response in patients with metastatic breast cancer.
Lisa A. Carey, MD, comments on the recent I-SPY 2 and KRISTINE findings, the I-SPY 2 program as a whole, and the work ahead in the neoadjuvant landscape of HER2-positive breast cancer.
Norman E. Sharpless, MD, professor of Medicine and Genetics, chair, the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses how oncologists can best manage toxicities associated with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.
Jose P. Zevallos, MD, MPH, FACS, assistant professor, director of Oncologic Research, University of North Carolina School of Medicine, discusses a study that examined the molecular profile of patients with HPV-positive oropharyngeal squamous cell carcinoma (SCC) stratified by smoking status.
Publication Bottom Border
Border Publication